Clinical Trials

The purpose of this study is to compare echocardiographic between acute and chronic severe AR patients at baseline and after surgical aortic valve replacement.

Measure by Doppler color automated integration cardiac stroke volumes and calculate regurgitant volume.

Classical echocardiographic assessment of heart valves is critical in determination of disease severity. However, echocardiography has only limited ability to predict how well an individual patient will do at time of surgery. New echocardiographic technology allows us to measure new, more refined parameters of your heart’s performance. This study is investigating whether these new parameters are better in predicting outcomes.

The purpose of this study is to assess the feasibility of color M mode and standard vena contracta measurements and compare these to novel measurements of aortic regurgitation in left ventricular assist devices (LVADs).

The purpose of this study is to continue the evaluation of non-FDA approved MR equipment software and hardware for imaging the heart and associated vasculature.

This study is being done to determine whether or not new blood test(s) can determine the severity of heart conditions. Aortic stenosis, hypertrophic cardiomyopathy, mitral regurgitation, aortic regurgitation, artificial heart valve regurgitation or stenosis, and tricuspid valve regurgitation associated with pacemaker leads are the cardiac disorders under study. The blood tests involve analysis for von Willebrand Factor antigen and activity, von Willebrand Factor multimers, and brain natriuretic peptide (BNP) levels. The results of the blood tests will be compared to the information from the clinically-indicated echocardiogram and one blood test compared to another.

This study (SE2030) will establish a platform of data to build the perfect stress echo test, suitable for all patients, anywhere, anytime, also quantitative and operator independent.